Antiangiogenic cancer drug drives lymphangiogenic metastasis.
Tumor blood vessel-destroying cancer drug induces development of tumor lymphatics that contribute to treatment failure.
George W. Woodruff School of Mechanical Engineering and Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332, USA. Email:susan.thomas@gatech.edu.
Susan Napier
SN
Thomas
D002292:Carcinoma, Renal Cell; D006801:Humans; D007680:Kidney Neoplasms; D042583:Lymphangiogenesis; D000077210:Sunitinib; D042582:Vascular Endothelial Growth Factor C
C467486:VEGFC protein, human; D042582:Vascular Endothelial Growth Factor C; D000077210:Sunitinib